Addition of Rigosertib to Gemcitabine Does Not Improve Efficacy in Pancreatic Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase 2/3 Randomized Study to Compare the Efficacy and Safety of Rigosertib Plus Gemcitabine vs Gemcitabine Alone in Patients With Previously Untreated Metastatic Pancreatic Cancer
Ann. Oncol 2015 Jun 19;[EPub Ahead of Print], BH O'Neil, AJ Scott, WW Ma, SJ Cohen, DL Aisner, AR Menter, MA Tejani, JK Cho, J Granfortuna, L Coveler, OO Olowokure, JC Baranda, M Cusnir, P Phillip, J Boles, R Nazemzadeh, M Rarick, DJ Cohen, J Radford, L Fehrenbacher, R Bajaj, V Bathini, P Fanta, J Berlin, AJ McRee, R Maguire, F Wilhelm, M Maniar, A Jimeno, CL Gomes, WA MessersmithFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.